Assessing treatment response to oral drugs for multiple sclerosis in real-world setting: a MAGNIMS Study.
Serena RuggieriLuca ProsperiniSarmad Al-ArajiPietro Osvaldo AnnovazziAlvino BiseccoOlga CiccarelliNicola De StefanoMassimo FilippiVinzenz FleischerNikos EvangelouChristian EnzingerAntonio GalloAfagh GarjaniSergiu GroppaShalom HaggiagMicheal KhalilMatteo LucchiniMassimiliano MirabellaXavier MontalbanCarlo PozzilliPaolo PreziosaJordi RíoMaria Assunta RoccaÀlex RoviraMaria L StromilloMauro ZaffaroniCarla TortorellaClaudio Gasperininull nullPublished in: Journal of neurology, neurosurgery, and psychiatry (2023)
Early relapses and substantial MRI activity in the first year of treatment are associated with worse short-term outcomes in patients treated with some of the oral DMTs.